Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
9 juli 2025
Gilde Healthcare’s private equity fonds bundelt Artinis en NIRx tot wereldleider in neuro-imaging
Gilde Healthcare kondigt vandaag de gecombineerde private equity investering aan in Artinis Medical Systems (Nederland) en NIRx Medical Technologies (Duitsland/Verenigde Staten), beiden pioniers op het gebied van functionele Near-Infrared Spectroscopy...
8 juli 2025
Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
9 juli 2025